Magnitude and polarization of p53-specific T-HELPER immunity in connection to leukocyte infiltration of colorectal tumors

被引:25
作者
Van der Burg, SH
Menon, AG
Redeker, A
Franken, KLMC
Drijfhout, JW
Tollenaar, RAEM
Hartgrink, HH
Van de Velde, CJH
Kuppen, PJK
Melief, CJM
Offringa, R
机构
[1] Leiden Univ, Med Ctr, Dept Immunohematol & Blood Transfus, NL-2300 RC Leiden, Netherlands
[2] Leiden Univ, Med Ctr, Dept Surg, Leiden, Netherlands
关键词
memory T cells; vaccination; cytokine; tumor infiltrating lymphocytes; antibodies;
D O I
10.1002/ijc.11419
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The tumor antigen p53 is mutated frequently and overexpressed in colorectal cancer. As a result, patients with this type of cancer commonly display p53-specific T-helper (Th) immunity. Examination of the cytokines produced by these Th-cells showed that a majority of the proliferative p53-specific T cell cultures produced none of the key cytokines (IFNgamma, TNFalpha, IL-4, IL-5 or IL-10), indicating that these p53-specific Th-responses are not polarized. In patients who exhibited p53-specific reactivity against multiple p53-epitopes, non-polarized responses could be found side by side with polarized Th-responses that produced INFgamma or other cytokines such is IL-10. Patients who exhibited p53-specific IFNgamma-producing Th cell-immunity before surgical excision of the tumor displayed higher numbers of tumor infiltrating intraepithelial leukocytes (p = 0.04) than patients lacking such responses, suggesting that the systemic presence of p53-specific Th-cells positively affects local tumor-immunity. Our data concerning the polarization-state of p53-specific Th immunity in colorectal cancer patients support the use of vaccine formulations that induce strong ThI-polarized p53-specific immunity to ensure proper (re-)programming of the anti-tumor response. (C) 2003 Wiley-Liss, Inc.
引用
收藏
页码:425 / 433
页数:9
相关论文
共 33 条
[1]   Human Th1 cells preferentially induce interleukin (IL)-1 beta while Th2 cells induce IL-1 receptor antagonist production upon cell/cell contact with monocytes [J].
Chizzolini, C ;
Chicheportiche, R ;
Burger, D ;
Dayer, JM .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1997, 27 (01) :171-177
[2]  
Cho Y, 2003, CANCER RES, V63, P1555
[3]   Dendritic cells directly trigger NK cell functions:: Cross-talk relevant in innate anti-tumor immune responses in vivo [J].
Fernandez, NC ;
Lozier, A ;
Flament, C ;
Ricciardi-Castagnoli, P ;
Bellet, D ;
Suter, M ;
Perricaudet, M ;
Tursz, T ;
Maraskovsky, E ;
Zitvogel, L .
NATURE MEDICINE, 1999, 5 (04) :405-411
[4]   Purification of His-tagged proteins by immobilized chelate affinity chromatography: The benefits from the use of organic solvent [J].
Franken, KLMC ;
Hiemstra, HS ;
van Meijgaarden, KE ;
Subronto, Y ;
den Hartigh, J ;
Ottenhoff, THM ;
Drijfhout, JW .
PROTEIN EXPRESSION AND PURIFICATION, 2000, 18 (01) :95-99
[5]   Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL [J].
Griffith, TS ;
Wiley, SR ;
Kubin, MZ ;
Sedger, LM ;
Maliszewski, CR ;
Fanger, NA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 189 (08) :1343-1353
[6]   P53 MUTATIONS IN HUMAN CANCERS [J].
HOLLSTEIN, M ;
SIDRANSKY, D ;
VOGELSTEIN, B ;
HARRIS, CC .
SCIENCE, 1991, 253 (5015) :49-53
[7]   The central role of CD4+ T cells in the antitumor immune response [J].
Hung, K ;
Hayashi, R ;
Lafond-Walker, A ;
Lowenstein, C ;
Pardoll, D ;
Levitsky, H .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (12) :2357-2368
[8]  
Ishida T, 1999, CLIN EXP IMMUNOL, V117, P244
[9]   Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines [J].
Mayordomo, JI ;
Loftus, DJ ;
Sakamoto, H ;
DeCesare, CM ;
Appasamy, PM ;
Lotze, MT ;
Storkus, WJ ;
Appella, E ;
DeLeo, AB .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (04) :1357-1365
[10]   Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes [J].
Melief, CJM ;
van der Burg, SH ;
Toes, REM ;
Ossendorp, F ;
Offringa, R .
IMMUNOLOGICAL REVIEWS, 2002, 188 :177-182